The pharmaceutical industry has lost another potential neuroscience development partnership after Novartis decided to discontinue its research program with Swedish biotechnology company BioArctic. The decision brings an end to an agreement signed in August 2025, which was designed to investigate a new approach to treating neurodegenerative disorders through improved drug delivery into the brain.
The collaboration centered on BioArctic’s proprietary BrainTransporter platform and an antibody developed by Novartis. Although the financial arrangement offered BioArctic an initial payment of $30 million, the agreement also included the possibility of securing another $772 million through development, regulatory and commercial milestones. Additional royalties, calculated on a tiered basis at mid-single-digit rates, were also included if a resulting medicine eventually reached the market.
However, those future financial opportunities have now disappeared following Novartis’ decision to close the program. BioArctic disclosed on November 2 that it had received formal notification from Novartis Pharma AG regarding the termination of the option, collaboration and licensing arrangement.
Despite losing the opportunity to earn the substantial milestone payments, BioArctic will retain the entire $30 million received when the agreement was established. The company also expects to record the outstanding portion of this advance as revenue during 2026. The amount that remains to be recognized has not been publicly specified.
Importantly, BioArctic clarified that the decision was driven by Novartis’ intention to discontinue the particular research program rather than concerns surrounding the BrainTransporter technology itself. No detailed explanation of the pharmaceutical company’s decision or the specific antibody target has been disclosed.
The research addressed a major obstacle in neuroscience: the blood-brain barrier, which protects brain tissue but also prevents many medicines from reaching it. Large biological treatments, including antibodies, have particular difficulty crossing this protective boundary. The problem has complicated efforts to develop therapies for Alzheimer’s, Parkinson’s, Huntington’s and amyotrophic lateral sclerosis.
BrainTransporter aims to use the transferrin receptor, a natural route through which iron enters the brain, to help transport therapeutic molecules from the bloodstream into brain tissue. BioArctic applies the platform to its own research and has established five external partnerships involving the technology.
The Novartis decision does not affect those separate arrangements. BioArctic continues collaborations with companies including Eli Lilly, Eisai and Bristol Myers Squibb. Its agreement with Lilly, announced in June 2026, includes a $30 million initial payment, potential milestone payments of up to $770 million and additional royalties.
BioArctic is also known for its role in developing Leqembi, an Alzheimer’s treatment partnered with Eisai. Its research portfolio includes programs directed at several neurodegenerative diseases.
Novartis has continued to investigate alternative approaches to brain delivery. In September 2026, it paid $125 million to exercise an option involving Sironax’s brain-delivery platform. The move indicates that ending the BioArctic program does not, by itself, mean the company is stepping away from efforts to overcome the blood-brain barrier.
For BioArctic, the termination removes the possibility of future milestone and royalty income from this program. Nevertheless, the company retains the upfront payment, while its other BrainTransporter collaborations remain in place.
BioArctic Loses Major Novartis Partnership in Neuroscience
BioArctic has suffered a setback after Novartis decided to terminate a neuroscience collaboration that could have been worth more than $800 million. The agreement, signed in August 2025, focused on combining BioArctic’s BrainTransporter technology with a proprietary Novartis antibody to explore a potential treatment for neurodegenerative disease. BioArctic
The Impact on BioArctic’s Future Strategy
The end of the collaboration creates a new challenge for the company’s business and development strategy. Large pharmaceutical partnerships often provide smaller biotechnology companies with financial resources, scientific expertise, and access to broader development capabilities. Losing a major partner can require a company to reassess its priorities and determine the best path forward for its research programs.
However, the termination of one agreement does not necessarily reflect the value of the underlying technology. Drug development programs can be discontinued for many reasons, including changes in portfolio priorities, evolving scientific data, competition, or shifting investment strategies. The company’s brain delivery platform will continue to be evaluated through its other research activities and partnerships.
Challenges in Neuroscience Drug Development
Developing medicines for neurological and neurodegenerative diseases remains one of the most complex areas of pharmaceutical research. The blood-brain barrier protects the brain from harmful substances but can also prevent potentially useful medicines from reaching their intended targets.
New delivery technologies aim to address this challenge by improving the ability of therapeutic molecules to reach the central nervous system. Success in this area could create opportunities for new treatments across a wide range of neurological conditions, including Alzheimer’s disease and other serious disorders.
